General Information:

Id: 2,575 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Homo sapiens
Reference: Feng Y et al.(2008) Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients Diabetes Care 31: 1939-1944 [PMID: 18599530]

Interaction Information:

Comment After 8 weeks of gliclazide therapy, mean fasting plasma glucose (FPG) was reduced from 11.1 mmol/l at baseline to 7.7 mmol/l. In cohort 1, all 25 SNPs were genotyped: Ser1369Ala of the ABCC8 gene and rs5210 of the KCNJ11 gene were significantly associated with decreases in FPG. Ser1369Ala was further genotyped in cohort 2 and confirmed the association identified in cohort 1. In the pooled analysis, compared with subjects with the Ser/Ser genotype, subjects with the Ala/Ala genotype had a 7.7% greater decrease in FPG, an 11.9% greater decrease in 2-h plasma glucose, and a 3.5% greater decrease in A1C after 8 weeks of treatment with gliclazide. In two independent cohorts of Chinese type 2 diabetic patients, we found consistent evidence that the Ser1369Ala variant in the ABCC8 gene can influence the antidiabetic efficacy of gliclazide.
Formal Description
Interaction-ID: 24219

decreases_activity of



after fasting, after treatment with gliclazide, the effective allele is G